Most of the conversation about GLP-1 medications and surgery has been about risk: whether the drugs slow stomach emptying and complicate anesthesia. A new analysis presented at the ANESTHESIOLOGY 2026 annual meeting looked at a different question, which is what happens to patients after the operation. The headline is favorable. The fine print is where the useful part is.
What the study did
Researchers led by Josephine Tolan, an anesthesiologist at UTHealth Houston’s Center for Outcomes Research, analyzed de-identified electronic health records from Epic Cosmos, a database covering more than 1,700 hospitals and 40,000 clinics. They included U.S. adults who had elective surgery lasting longer than 60 minutes and stayed in the hospital at least 24 hours afterward, between January 2016 and December 2024.
Of 2,028,601 patients, 145,610 (about 7%) were taking a GLP-1 medication. The researchers matched users with similar non-users and compared outcomes.
What it found
- Major cardiovascular complications (heart attack, heart injury, stroke, or death): 11% lower odds in GLP-1 users.
- Postoperative infections (surgical site infections, urinary tract infections, pneumonia, and sepsis): 8% lower odds in GLP-1 users.
Those are modest differences, not dramatic ones. They are also reported as odds, which describe relative differences. The coverage we found does not give the raw event rates, so we cannot tell you how many fewer complications that means per thousand patients. A relative reduction applied to a rare event can be a very small absolute change.
What it does not establish
It does not show the medication caused the difference. This is a retrospective analysis, and people were not randomly assigned to take a GLP-1. The authors say plainly that it does not prove cause and effect. Matching helps make the groups comparable, but it can only balance what the database recorded. People who are prescribed these drugs may differ from those who are not in insurance coverage, access to follow-up care, and how closely their health is already managed. None of that fully shows up in a record.
The mechanisms are guesses. The authors point to possibilities: weight loss, better blood pressure and blood sugar control, lower inflammation, protection of heart muscle under stress, and a stronger immune response when glucose is better controlled. These are reasonable hypotheses. They are not findings from this study.
It says little about the question clinicians actually worry about. The coverage we reviewed reported no findings on aspiration, the concern that led anesthesia groups to issue guidance about GLP-1 use before procedures. A study showing fewer infections afterward does not answer whether anything needs to be done differently beforehand.
It was a conference presentation. Findings presented at a meeting have not gone through the full peer review of a published paper. Funding, confidence intervals, and the matching method were not described in the summaries available to us.
Why you should not act on this
Do not start, stop, hold, or continue any medication because of this study. If you have surgery scheduled, the question of what to do with a GLP-1 belongs to your surgical team and the licensed clinician who prescribes it, who can look at the procedure, the anesthesia plan, and your history. Guidance on that has varied and has been shifting, and a general article cannot replace it. Tell everyone involved in your care what you take.
The part that applies to compounded medications
Much of the database behind a study like this reflects manufactured, branded GLP-1 products, along with the patients who were prescribed them. The evidence does not transfer to a compounded preparation.
Compounded semaglutide and tirzepatide are prepared by state-licensed pharmacies for an individual patient. They are not FDA-approved, and no analysis like this one has tested them for surgical outcomes. If a company cites research like this to suggest its compounded product will protect you around surgery, it is claiming more than the study covers. You can read how we describe that distinction in our FAQ.
What to take from it
The most reasonable reading is narrow: in a very large record set, people taking GLP-1 medications did not do worse after elective surgery, and on two measures they did somewhat better. That is a signal worth testing in better-designed studies, not a benefit anyone can count on. If you want to understand how provider-guided care works before any medication decision, our how it works page walks through each step.
This post is general information, not medical advice. It does not describe a benefit of any NoBsRx program and it is not a claim that any medication will improve surgical outcomes. Compounded medications are not FDA-approved. Treatment is never guaranteed. Eligibility and every treatment decision, including what to do with any medication before a procedure, are made by independent licensed providers based on an individual clinical assessment, and availability varies by state. Do not start, stop, or change any treatment based on an article.